ImmuCell (NASDAQ:ICCC) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
Product sales rose 11.5% year ove
ImmuCell (NASDAQ:ICCC) reported a record first quarter of 2026, with management saying the company’s narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales.
President and Chief Executive Officer Olivier te Boekhors
In a significant strategic shift that marks the end of a multi-year regulatory odyssey, ImmuCell Corporation (Nasdaq: ICCC) announced late yesterday, December 23, 2025, that it has received another Technical Section Incomplete Letter from the U.S. Food and Drug Administration (FDA) regarding its subclinical mastitis treatment, Re-Tain. The letter,
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Eli Lilly and Co., and Shopify Inc., as well as a micro-cap stock ImmuCell Corp.
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
